Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTRA-2112 for Intestinal Malabsorption in Preterm Infants
NCT02510560Phase 3Terminated
- Sponsor
- Elgan Pharma
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of elgn-gi in intestinal malabsorption, sponsored by Elgan Pharma. Started Oct 2016; status: terminated.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on NCT02510560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510560.